StockData
Accustem Sciences Inc. logo

Accustem Sciences Inc. (ACUT) stock

ACUTOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$0.15+0.00 (0.00%)

Close on Oct 16, 2026Market cap $2.37MP/E –Yield –

Accustem Sciences r&d expenses

Research and development expenses are spending on new products and technology.

Accustem Sciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $355.70K, up 119.7% year over year. For fiscal 2025 it was $281.01K, up 103.2% from the year before. The highest annual figure on record is $281.01K in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$281.01K+103.2%
FY2024Dec 31, 2024$138.32K-1.0%
FY2023Dec 31, 2023$139.66K-47.7%
FY2022Dec 31, 2022$266.93K+264.0%
FY2021Dec 31, 2021$73.34K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$43.71K-27.4%
Q1 FY2026Mar 31, 2026$119.53K+321.7%
Q4 FY2025Dec 31, 2025$119.74K+185.3%
Q3 FY2025Sep 30, 2025$72.72K+131.5%
Q2 FY2025Jun 30, 2025$60.20K+44.2%
Q1 FY2025Mar 31, 2025$28.35K+22.2%
Q4 FY2024Dec 31, 2024$41.97K-53.1%
Q3 FY2024Sep 30, 2024$31.41K+57.4%
Q2 FY2024Jun 30, 2024$41.75K+186.4%
Q1 FY2024Mar 31, 2024$23.20K+48.7%
Q4 FY2023Dec 31, 2023$89.54K-32.7%
Q3 FY2023Sep 30, 2023$19.95K-65.8%
Q2 FY2023Jun 30, 2023$14.58K-73.2%
Q1 FY2023Mar 31, 2023$15.60K-26.2%
Q4 FY2022Dec 31, 2022$133.12K+403.0%
Q3 FY2022Sep 30, 2022$58.27K+312.5%
Q2 FY2022Jun 30, 2022$54.40K+80.1%
Q1 FY2022Mar 31, 2022$21.14K+697.8%
Q4 FY2021Dec 31, 2021$26.47K–
Q3 FY2021Sep 30, 2021$14.13K–
Q2 FY2021Jun 30, 2021$30.20K–
Q1 FY2021Mar 31, 2021$2.65K–

More Accustem Sciences figures

See a number that looks wrong?